title: 5alpha-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency.
abstract: Norethisterone (NET), a 19-nor synthetic progestin, undergoes enzyme-mediated 5alpha-reduction and exerts potent androgenic effects in target organs. To investigate its mode of androgenic action we examined, in a comparative manner, the in vitro metabolism of NET and testosterone (T), as well as the binding affinities to androgen receptors (AR) and the androgenic potency of NET, T, and their 5alpha-reduced derivatives. Bioconversion of [3H]-NET and [3H]-T was studied in rat prostate homogenates, AR binding affinity was assessed in rat ventral prostates using [3H]-mibolerone as the radioligand, and the androgenic potency was evaluated by the increase of beta-glucuronidase activity in the mouse kidney, and by the growth of accessory sex organs in castrated male rats. The results demonstrated that 5alpha-NET displayed a higher AR binding affinity but a significantly lower androgenic potency than unchanged NET. The bioconversion studies indicated that the metabolism of NET was similar to that of T, although to a lesser extent, thus ruling out the possibility that the synthetic progestin metabolizes rapidly into less active derivatives. To investigate the nature of the paradoxical effect of 5alpha-reduction upon the NET molecule, the interaction with AR and the androgenic potency of T, 19-nortestosterone (19norT), 17alpha-ethynyl testosterone (ET) and their 5alpha-reduced derivatives were examined. The results of AR binding studies revealed that 5alpha-reduction of T and ET significantly enhanced their affinities, and that the 5alpha-derivative of 19norT displayed a similar binding affinity to that exhibited by 19norT. In terms of biological activity, the results showed that 5alpha-reduction of T and 19norT significantly increased their androgenic potency, whereas 5alpha-reduction of ET resulted in a significant diminution of its androgenicity in a manner similar to that observed with the 5alpha-reduction of NET. When NET and 19norT were simultaneously administered with 5alpha-dihydrotestosterone they exhibited a potent synandrogenic activity, an effect that was cancelled by their 5alpha-reduction. Interestingly, ET displayed an antiandrogenic activity, an effect that was also suppressed by its 5alpha-reduction. The overall results demonstrated a distinctive, paradoxical effect of 5alpha-reduction upon the NET molecule, which was different from that seen in naturally occurring androgens, and which suggests that the presence of the 17alpha-ethynyl group plays a key role in this phenomenon. The data provided further evidence that the metabolism of synthetic contraceptive progestins modulates the expression of their hormone-like actions.
authors.affiliation: Department of Reproductive Biology, UAM-Iztapalapa, Mexico City, Mexico.
authors.forename: A E
authors.initials: AE
authors.lastname: Lemus
authors.forename: J
authors.initials: J
authors.lastname: Enríquez
authors.forename: G A
authors.initials: GA
authors.lastname: García
authors.forename: I
authors.initials: I
authors.lastname: Grillasca
authors.forename: G
authors.initials: G
authors.lastname: Pérez-Palacios
mesh_terms: D000728:Androgens / Q000502:physiology; D000818:Animals; D001667:Binding, Competitive; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005003:Ethisterone / Q000378:metabolism / Q000494:pharmacology; D005966:Glucuronidase / Q000187:drug effects / Q000378:metabolism*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009277:Nandrolone / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D009640:Norethindrone / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology*; D009919:Orchiectomy; D009929:Organ Size / Q000187:drug effects; D010084:Oxidation-Reduction; D045167:Progesterone Congeners / Q000378:metabolism; D011467:Prostate / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011944:Receptors, Androgen / Q000378:metabolism*; D012669:Seminal Vesicles / Q000187:drug effects / Q000254:growth & development; D013329:Structure-Activity Relationship; D013739:Testosterone / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D014316:Tritium
chemical_list: D000728:Androgens; D045167:Progesterone Congeners; D011944:Receptors, Androgen; D014316:Tritium; D013739:Testosterone; D009277:Nandrolone; C100075:mibolerone; D005966:Glucuronidase; D005003:Ethisterone; D009640:Norethindrone